Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice

Journal of Neurochemistry

Volumn 70, Issue 5, 1998, Pages 1973-1978

  Gainetdinov, Raul R ^a,c   Fumagalli, Fabio ^a,d   Wang, Yan Min ^a   Jones, Sara R ^a   Levey, Allan I ^b   Miller, Gary W ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^d University of Pharmacological Sciences   (Italy)

Author keywords

Dopamine transporter; Glial fibrillary acidic protein; MPTP neurotoxicity; Vesicular monoamine transporter

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN MONOAMINE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; NEUROTOXIN; TRITIUM;

ANIMAL MODEL; ARTICLE; BRAIN SYNAPTOSOME; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; KNOCKOUT MOUSE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ANIMALIA; TRITIUM;

EID: 0031959343     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70051973.x     Document Type: Article

References (29)

1. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Mol. Pharmacol. 47, 779-786.
2. Chiang C. S., Stalder A., Samimi A., and Campbell I. L. (1994) Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev. Neurosci. 16, 212-222.
3. Chomczynski P. and Sacchi N. (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
4. Eng L. F. (1985) Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J. Neuroimmunol. 8, 203-214.
5. Erickson J. D., Eiden L. E., and Hoffman B. J. (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 89, 10993-10997.
6. Erickson J. D., Schafer M. K.-H., Bonner T. I., Eiden L. E., and Weihe E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 93, 5166-5171.
7. Fon E. A., Pothos E. N., Sun B.-C., Killen N., Sulzer D., and Edwards R. H. (1997) Vascular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 1271-1283.
8. Francis J. W., Von Visger J., Markelonis G. J., and Oh T. H. (1995) Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17, 7-12.
9. Fumagalli F., Jones S. R., Caron M. G., Seidler F. J., and Slotkin T. A. (1996) Expression of mRNA coding for the serotonin transporter in aged vs. young brain: differential effects of glucocorticoids. Brain Res. 719, 225-228.
10. Gainetdinov R. R., Fumagalli F., Jones S. R., and Caron M. G. (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325.
11. German D. C., Nelson E. L., Liang C. L., Cpeciale S. G., Sinton C. M., and Sonsalla P. K. (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mice. Neurodegeneration 5, 299-312.
12. Giovanni A., Sieber B. A., Heikkila R. E., and Sonsalla P. K. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J. Pharmacol. Exp. Ther. 270, 1000-1007.
13. Hallman H., Lange J., Olson L., Strömberg I., and Jonsson G. (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J. Neurochem. 44, 117-127.
14. Heikkila R. E., Manzino L., Cabbat F. S., and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
15. Javitch J. A., D'Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173-2177.
16. Kopin I. J. (1992) Features of the dopaminergic neurotoxin MPTP. Ann. NY Acad. Sci. 648, 96-104.
17. Liu Y. and Edwards R. H. (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125-156.
18. + toxicity encodes a vesicular amine transporter. Cell 70, 539-551.
19. Miller G. W., Staley J. K., Heilman C. J., Perez J. T., Mash D. C., Rye D. B., and Levey A. I. (1997) Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41, 530-539.
20. O'Callaghan J. P., Miller D. B., and Reinhard J. F. Jr. (1990) Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 521, 73-80.
21. Peter D., Jimenez J., Liu Y., Kim J., and Edwards R. H. (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269, 7231-7237.
22. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., and Edwards R. H. (1995) Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 6179-6188.
23. Pileblad E., Fornstedt B., Clark D., and Carlsson A. (1985) Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. J. Pharm. Pharmacol. 37, 707-712.
24. Reinhard J. F. Jr., Miller D. B., and O'Callaghan J. P. (1988) The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Neurosci. Lett. 95, 246-251.
25. Snyder S. H. and D'Amato R. J. (1986) MPTP, a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36, 250-258.
26. Takahashi N., Miner L. L., Sora I., Ujike H., Revay R. S., Kostic V., Jackson-Lewis V., Przedborski S., and Uhl G. R. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA 94, 9938-9943.
27. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
28. Wang Y. M., Gainetdinov R. R., Fumagalli F., Xu F., Jones S. R., Bock C. B., Miller G. W., Wightman R. M., and Caron M. G. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285-1296.
29. Wilson J., Levey A. I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H., Hornykiewicz O., Pifl C., and Kish S. (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47, 718-726.